Filiz Başak Cengiz Ergin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Filiz Başak Cengiz Ergin has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Fatih Ezgu
Division of Pediatric Genetics, Department of Pediatrics Faculty of Medicine, Gazi University Ankara Türkiye
6 shared publications - Aslı İnci
Department of Pediatric Nutrition and Metabolism, School of Medicine, Gazi University, Ankara 06500, Türkiye
3 shared publications - Leyla Tümer
Department of Pediatrics, Division of Pediatric Metabolism, Gazi University Faculty of Medicine, Ankara 06500, Türkiye
3 shared publications - Gürsel Biberoğlu
GAZİ ÜNİVERSİTES
2 shared publications İlYas Okur
Department of Pediatric Metabolism Gazi University Faculty of Medicine Ankara Turkey
2 shared publicationsİlyas Okur
GAZİ ÜNİVERSİTES
2 shared publications
Latest Publications
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- 8 October 2026
- Published by Wiley in Clinical Genetics
A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome
To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70700
Hemophagocytic Lymphohistiocytosis in a Patient With Gaucher Disease Having a Homozygous STXBP3 Variant
- 16 September 2026
- Published by Wiley in Pediatric Blood & Cancer
- p. e70700
Hemophagocytic Lymphohistiocytosis in a Patient With Gaucher Disease Having a Homozygous STXBP3 Variant
- Open Access
Transcriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease
Background: Gaucher disease (GD) arises from pathogenic variants in the GBA1 gene and is known for its wide range of clinical presentations—a variability that genotype alone cannot adequately account for. Objective: This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. Methods: We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. Results: Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (DDIT4, RPH3A, SAMSN1) trended toward higher expression in patients versus controls, and interferon-stimulated genes (ISG15, RSAD2, IFI44L) were more elevated in M2 than in M1. Conclusions: Taken together, these findings suggest that factors beyond genetics—whether epigenetic, environmental, or otherwise—may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same.
Open AccessTranscriptomic Profiling of Monozygotic Twins with Type 1 Gaucher Disease
Background: Gaucher disease (GD) arises from pathogenic variants in the GBA1 gene and is known for its wide range of clinical presentations—a variability that genotype alone cannot adequately account for. Objective: This study aimed to explore transcriptomic factors that might help explain why two genetically identical twins with type 1 GD developed noticeably different clinical outcomes. Methods: We isolated peripheral blood mononuclear cells from both twins and two age-matched controls, then differentiated them into macrophages in vitro before conducting RNA sequencing. Gene expression differences were analyzed using established bioinformatics pipelines, and a subset of genes were subsequently assessed by quantitative real-time PCR (qRT-PCR) to confirm the sequencing findings. Results: Both twins shared a GD-associated transcriptional signature broadly reflecting immune activation and lysosomal stress. Interestingly, the twin who experienced systemic complications had a relative enrichment of interferon-responsive transcripts, while the less severely affected twin showed more pronounced suppression of small nucleolar RNA clusters. That said, neither difference held up after correcting for multiple comparisons, so these patterns are best viewed as exploratory trends rather than definitive findings. The qRT-PCR results lend partial support to this picture: stress- and immune-related genes (DDIT4, RPH3A, SAMSN1) trended toward higher expression in patients versus controls, and interferon-stimulated genes (ISG15, RSAD2, IFI44L) were more elevated in M2 than in M1. Conclusions: Taken together, these findings suggest that factors beyond genetics—whether epigenetic, environmental, or otherwise—may play a meaningful role in shaping how GD manifests differently even between individuals with identical DNA. Although the data are preliminary, they point to transcriptomic profiling, paired with targeted validation, as a useful starting point for building hypotheses about why this disease looks so different from one patient to the next, even when the underlying mutation is the same.
- Open Access
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Expert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
- 20 June 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (3) , 585-594
Open AccessExpert opinion on clinical presentation, diagnosis and treatment of infantile onset pompe disease: a delphi study in Türkiye
Background/aim: Pompe disease (acid maltase deficiency, glycogen storage disease type II, OMIM #606800) is an autosomal recessive disorder characterized by lysosomal acid-α-glucosidase deficiency. The infantile-onset type of the disease is mainly characterized by cardiomegaly, hypotonia, and a high mortality rate. This study aimed to create a national consensus about infantile-onset Pompe disease (IOPD) to raise awareness among clinicians and standardize diagnosis and treatment approaches in Türkiye. Materials and methods: The Gazi University Division of Metabolic Diseases and Nutrition developed this expert opinion consensus and expanded it to include metabolism specialists across Türkiye. A systematic literature review was performed, and the Delphi method was used to evaluate the results. Results: Seventeen conclusive questions were produced about clinical presentation, diagnosis, and treatment, and 14 reached a consensus. Consensus was reached that general hypotonia is one of the most important findings, and agreement was also achieved on the starting dose of treatment for presymptomatic patients. The contributors agreed that gene therapy is a good treatment option for IOPD in the future. Conclusion: The topics related to this consensus will help physicians in Türkiye and elsewhere with high incidence rates of IOPD,especially regarding diagnosis and treatment decisions.
- 18 July 2022
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 23 (3) , 322-325
MİTOKONDRİYAL HASTALIK NEDENİYLE TETKİK EDİLEN HASTALARDA M.16189T>C DEĞİŞİKLİĞİNİN METABOLİK SENDROM AÇISINDAN İNCELENMESİ
AMAÇ: Metabolik sendrom, obezite, yüksek düzeyde düşük yoğunluklu kolesterol düzeyi (LDL), trigliserit düzeyi (TG) ve insuline duyarlılık ile karakterize olan günümüzde sıklığı giderek artan bir bozukluktur. Metabolik sendromun etiyopatogenezinde hem genetik hem de çevresel nedenlerin rol oynadığı bilinmektedir. Özellikle mitokondriyal DNA’da oluşan m.16189T>C değişikliğinin bu hastalıkla ilişkili olduğu gösterilmiştir. Bu çalışmada mitokondriyal hastalık şüphesi ile başvuran hastalarda saptanan m.16189T>C değişikliğinin klinik ve laboratuvar bulgularının incelenmesi amaçlanmıştır.GEREÇ VE YÖNTEM: Kliniğimize 2019 - 2020 yılları arasında mitokondriyal hastalık şüphesi ile gelen hastalardan m.16189T>C değişikliği olan hastalar çalışmaya alınmıştır. Hastaların klinik ve laboratuvar bulguları mitokondriyal hastalık şüphesi taşıması nedeniyle periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.16189T>C değişikliği olan hastalar saptanarak çalışmaya dahil edilmiştir. Bu hastaların klinik ve laboratuvar bulguları metabolik sendrom açısından incelenmiştir.BULGULAR: 1 yıllık süre içinde 55 hastanın 11’inde mitokondriyal genom analizinde m.16189T>C değişikliği saptanmıştır (%20). Fizik muayene bulgularında, hiçbir hastada fazla tartı ve obezite saptanmamıştır. Hastaların glukoz, LDL ve trigliserit düzeyleri normal aralıkta bulunmuştur.SONUÇ: Hasta grubumuzda oldukça yüksek oranda saptanan bu değişikliğin metabolik sendrom ile ilişkisi gösterilememiş ve polimorfizm olarak değerlendirilmiştir. Ancak mitokondriyal hastalık şüphesi ile gelen bu hastaların kullandığı ilaçların, beslenme şekillerinin ve hastalığın patofizyolojisinin bu metabolik sendromu etkileyen çevresel faktörler olabileceği ön görülebilir.
- 18 July 2022
- Published by Afyon Kocatepe University in Kocatepe Tıp Dergisi
- Vol. 23 (3) , 322-325
MİTOKONDRİYAL HASTALIK NEDENİYLE TETKİK EDİLEN HASTALARDA M.16189T>C DEĞİŞİKLİĞİNİN METABOLİK SENDROM AÇISINDAN İNCELENMESİ
AMAÇ: Metabolik sendrom, obezite, yüksek düzeyde düşük yoğunluklu kolesterol düzeyi (LDL), trigliserit düzeyi (TG) ve insuline duyarlılık ile karakterize olan günümüzde sıklığı giderek artan bir bozukluktur. Metabolik sendromun etiyopatogenezinde hem genetik hem de çevresel nedenlerin rol oynadığı bilinmektedir. Özellikle mitokondriyal DNA’da oluşan m.16189T>C değişikliğinin bu hastalıkla ilişkili olduğu gösterilmiştir. Bu çalışmada mitokondriyal hastalık şüphesi ile başvuran hastalarda saptanan m.16189T>C değişikliğinin klinik ve laboratuvar bulgularının incelenmesi amaçlanmıştır.GEREÇ VE YÖNTEM: Kliniğimize 2019 - 2020 yılları arasında mitokondriyal hastalık şüphesi ile gelen hastalardan m.16189T>C değişikliği olan hastalar çalışmaya alınmıştır. Hastaların klinik ve laboratuvar bulguları mitokondriyal hastalık şüphesi taşıması nedeniyle periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.16189T>C değişikliği olan hastalar saptanarak çalışmaya dahil edilmiştir. Bu hastaların klinik ve laboratuvar bulguları metabolik sendrom açısından incelenmiştir.BULGULAR: 1 yıllık süre içinde 55 hastanın 11’inde mitokondriyal genom analizinde m.16189T>C değişikliği saptanmıştır (%20). Fizik muayene bulgularında, hiçbir hastada fazla tartı ve obezite saptanmamıştır. Hastaların glukoz, LDL ve trigliserit düzeyleri normal aralıkta bulunmuştur.SONUÇ: Hasta grubumuzda oldukça yüksek oranda saptanan bu değişikliğin metabolik sendrom ile ilişkisi gösterilememiş ve polimorfizm olarak değerlendirilmiştir. Ancak mitokondriyal hastalık şüphesi ile gelen bu hastaların kullandığı ilaçların, beslenme şekillerinin ve hastalığın patofizyolojisinin bu metabolik sendromu etkileyen çevresel faktörler olabileceği ön görülebilir.
- Open Access
- 19 January 2022
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 23 (1) , 1-4
A Turkish case of incontinentia pigmenti with a deletion mutation at Inhibitor of kappa B kinase gamma gene
Background: Incontinentia pigmenti (IP) is a rare X-linked dominant disorder affecting the skin and other ectodermal tissues that is caused by a mutation of the IKBKG/NEMO gene. Case presentation: We describe a Turkish family with IP. Sanger sequencing was performed in our patient with IP, and we identified DNA variant c.172_173delAA (p.Asn58SerfsTer79) in IKBKG. We found the same mutation in the patient's mother and grandmother. Conclusion: Our report expands the mutation spectrum in this disorder and provides valuable information on the importance of the IKBKG. Our study shows that confirmation of the mutation analysis of IP in the suspected cases is necessary for future planning pregnancies.
- 19 January 2022
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 23 (1) , 1-4
Open AccessA Turkish case of incontinentia pigmenti with a deletion mutation at Inhibitor of kappa B kinase gamma gene
Background: Incontinentia pigmenti (IP) is a rare X-linked dominant disorder affecting the skin and other ectodermal tissues that is caused by a mutation of the IKBKG/NEMO gene. Case presentation: We describe a Turkish family with IP. Sanger sequencing was performed in our patient with IP, and we identified DNA variant c.172_173delAA (p.Asn58SerfsTer79) in IKBKG. We found the same mutation in the patient's mother and grandmother. Conclusion: Our report expands the mutation spectrum in this disorder and provides valuable information on the importance of the IKBKG. Our study shows that confirmation of the mutation analysis of IP in the suspected cases is necessary for future planning pregnancies.
- 31 December 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (4) , 679-682
The Effect of m.3010G> A Variant on Cyclic Vomiting Syndrome in Turkish Population
Giriş ve Amaç: Siklik kusma sendromu (SKS) sık görülen gastrointestinal fonksiyonel bir düzensizliktir. Gastrointestinal fonksiyonel düzensizliklerin mitokondriyal polimorfizmlerle ilişkili olduğu gösterilmiştir. Bu çalışmada, m.3010G>A değişikliğini taşıyan hastalarda klinik bulguların incelenmesi amaçlanmıştır. Gereç ve Yöntemler: Kliniğimize mitokondriyal hastalık şüphesi ile gelen 55 hastadan, periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.3010G>A değişikliği olan hastalar saptanmıştır. Bu hastalarda klinik bulgular incelenmiştir. Bulgular: Toplam 55 hastada yapılan mitokondriyal genom analizinde altı farklı hastada m.3010G>A değişikliği saptanmıştır. m.3010G>A değişikliği saptanan bu hasta grubunda SKS ile ilgili klinik bulgular saptanmamıştır. Sonuç: Daha önce yapılan çalışmalarda m.3010G>A değişikliğinin SKS ile ilişkili olabileceği gösterilmiş olsa da bizim çalışmamızda katılan hastalarda bu bulgular bulunmamaktadır. Yine de SKS’nin ileri yaşlarda da ortaya çıkabileceği göz önünde bulundurulmalı ve yakın takip edilmelidir.
- 31 December 2021
- Published by Celal Bayar Universitesi Saglık Bilimleri Enstitusu Dergisi in Celal Bayar Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi
- Vol. 8 (4) , 679-682
The Effect of m.3010G> A Variant on Cyclic Vomiting Syndrome in Turkish Population
Giriş ve Amaç: Siklik kusma sendromu (SKS) sık görülen gastrointestinal fonksiyonel bir düzensizliktir. Gastrointestinal fonksiyonel düzensizliklerin mitokondriyal polimorfizmlerle ilişkili olduğu gösterilmiştir. Bu çalışmada, m.3010G>A değişikliğini taşıyan hastalarda klinik bulguların incelenmesi amaçlanmıştır. Gereç ve Yöntemler: Kliniğimize mitokondriyal hastalık şüphesi ile gelen 55 hastadan, periferik kandan mitokondriyal DNA izolasyonu yapılmıştır. Yeni nesil DNA dizileme ile tüm mitokondriyal genom DNA dizi analizi yapılarak m.3010G>A değişikliği olan hastalar saptanmıştır. Bu hastalarda klinik bulgular incelenmiştir. Bulgular: Toplam 55 hastada yapılan mitokondriyal genom analizinde altı farklı hastada m.3010G>A değişikliği saptanmıştır. m.3010G>A değişikliği saptanan bu hasta grubunda SKS ile ilgili klinik bulgular saptanmamıştır. Sonuç: Daha önce yapılan çalışmalarda m.3010G>A değişikliğinin SKS ile ilişkili olabileceği gösterilmiş olsa da bizim çalışmamızda katılan hastalarda bu bulgular bulunmamaktadır. Yine de SKS’nin ileri yaşlarda da ortaya çıkabileceği göz önünde bulundurulmalı ve yakın takip edilmelidir.